The Welsh Government already has substantial control of onshore oil and gas activities through planning controls and environmental regulation as these are devolved. Through the relevant planning authorities in Wales, the Welsh Government has the power to take decisions on individual shale projects.<\/p>
The Government will implement the St David\u2019s Day Agreement in full which includes devolving licensing functions for onshore oil and gas exploration to Welsh Ministers.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4282", "label" : {"_value" : "Biography information for Lord Bourne of Aberystwyth"} } , "answeringMemberPrinted" : {"_value" : "Lord Bourne of Aberystwyth"} , "dateOfAnswer" : {"_value" : "2015-06-03", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-03T15:24:13.787Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "63"} , "answeringDeptShortName" : {"_value" : "Energy and Climate Change"} , "answeringDeptSortName" : {"_value" : "Energy and Climate Change"} , "date" : {"_value" : "2015-05-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Fracking: Wales"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether onshore fracking for gas in Wales will become the responsibility of the National Assembly for Wales.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/547", "label" : {"_value" : "Biography information for Lord Wigley"} } , "tablingMemberPrinted" : [{"_value" : "Lord Wigley"} ], "uin" : "HL70"} , {"_about" : "http://data.parliament.uk/resources/346833", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/346833/answer", "answerText" : {"_value" : "
The Home Office target for replying to Lords correspondence is 20 working days. The Immigration Minister responded on 2 June.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1091", "label" : {"_value" : "Biography information for Lord Bates"} } , "answeringMemberPrinted" : {"_value" : "Lord Bates"} , "dateOfAnswer" : {"_value" : "2015-06-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-04T14:57:13.763Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "1"} , "answeringDeptShortName" : {"_value" : "Home Office"} , "answeringDeptSortName" : {"_value" : "Home Office"} , "date" : {"_value" : "2015-05-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Peers: Correspondence"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government when they will respond to the letter sent by Lord Wigley to the Home Secretary on 29 April concerning Lisa Hughes, an Argentine citizen of Welsh descent and the case for her to be allowed to remain in the United Kingdom until 9 August to participate in celebrations of the establishment of the Welsh settlement in Patagonia in 1865.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/547", "label" : {"_value" : "Biography information for Lord Wigley"} } , "tablingMemberPrinted" : [{"_value" : "Lord Wigley"} ], "uin" : "HL71"} , {"_about" : "http://data.parliament.uk/resources/346835", "AnsweringBody" : [{"_value" : "Department for Energy and Climate Change"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/346835/answer", "answerText" : {"_value" : "
This is a commercial matter for Cavendish Fluor Partnership who were last year appointed by the Nuclear Decommissioning Authority (NDA) as the Magnox Parent Body Organisation to deliver greater effectiveness and efficiency in the decommissioning of the 12 Magnox sites. The Magnox programme is a closure programme and, inevitably, this means that workforce numbers will reduce as the sites are decommissioned.<\/p>
The Government sympathises with those directly affected and is assured by the NDA, which has been fully involved in discussions with Magnox on its new organisational structure, that the company will implement its plans in line with industry best practice in order to mitigate the impact of job losses, and with fairness and respect for its staff.<\/p>
Nothing will be done to compromise safety and security. The independent regulator, the Office for Nuclear Regulation (ONR) is also content with the programme.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4282", "label" : {"_value" : "Biography information for Lord Bourne of Aberystwyth"} } , "answeringMemberPrinted" : {"_value" : "Lord Bourne of Aberystwyth"} , "dateOfAnswer" : {"_value" : "2015-06-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-06-02T13:47:37.6Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "63"} , "answeringDeptShortName" : {"_value" : "Energy and Climate Change"} , "answeringDeptSortName" : {"_value" : "Energy and Climate Change"} , "date" : {"_value" : "2015-05-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nuclear Power Stations: Decommissioning"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the recently announced reduction in the number of employees working on the decommissioning of nuclear power stations and the possible safety implications for those locations.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/547", "label" : {"_value" : "Biography information for Lord Wigley"} } , "tablingMemberPrinted" : [{"_value" : "Lord Wigley"} ], "uin" : "HL73"} , {"_about" : "http://data.parliament.uk/resources/228381", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/228381/answer", "answerText" : {"_value" : "
Prior to the establishment of the National Institute for Health Research (NIHR) in April 2006, the main part of the total health research expenditure of the Department of Health was devolved to and managed by National Health Service organisations. The NHS organisations reported on their use of these allocations in annual research and development reports. These reports identify total, aggregated expenditure on national priority areas, including cancer. They do not provide details of research into particular cancer sites. From April 2006 to March 2009, transitional research funding was allocated to these organisations at reducing levels. At the same time, an increasing amount of NHS research funding was awarded competitively through new NIHR programmes and schemes.<\/p>
<\/p>
<\/p>
<\/p>
Expenditure by the NIHR through research programmes, research centres and units, and research training awards on mesothelioma research is shown in the following table:<\/p>
<\/p>
<\/p>
<\/p>
2006-07<\/p> £ million<\/p><\/td> | 2007-08<\/p> £ million<\/p><\/td> | 2008-09<\/p> £ million<\/p><\/td> | 2009-10<\/p> £ million<\/p><\/td> | 2010-11<\/p> £ million<\/p><\/td> | 2011-12<\/p> £ million<\/p><\/td> | 2012-13<\/p> £ million<\/p><\/td> | 2013-14<\/p> £ million<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.0<\/p><\/td> | 0.2<\/p><\/td> | 0.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Total spend by the NIHR on mesothelioma research is higher than this because expenditure by the NIHR Clinical Research Network (CRN) on this topic cannot be disaggregated from total CRN expenditure.<\/p> <\/p> <\/p> <\/p> The NIHR invests in infrastructure for experimental medicine to translate scientific developments into benefits for patients. This infrastructure includes biomedical centres and units, clinical research facilities, and experimental cancer medicine centres. The NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London has contributed to the funding of recent research on the use of TRAIL (tumour necrosis factor-related apoptosis-inducing ligand)-expressing mesenchymal stem cells to reduce tumour growth in malignant mesothelioma.<\/p> <\/p> <\/p> <\/p> The following table provides expenditure by the Medical Research Council on research related to mesothelioma over the past six years. Information on spend from 2004-05 to 2007-08 was not available within the timescale.<\/p> <\/p> <\/p> <\/p>
|